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Unlike HIV disease or tuberculosis (TB), both of which 
are also major threats to public heath throughout the 
tropics, uncomplicated malaria (of whatever species) is 
relatively cheaply and rapidly cured, usually in out- 
patients. However, in common with both HIV and TB 
(but to varying degrees), control of malaria is threatened 
by inadequate resources and drug resistance. Africa 
carries the greatest burden of malaria mortality and 
morbidity; by no coincidence, it is also Africa that 
is most resource-limited, This review will focus on 
falciparum malaria in Africa. The control of mortality 
and morbidity depends on the best use of very sparse 
resources. The main modalities available are as follows. 
(1) Prevention of infection by the use of insecticide- 
treated bed-nets has a major impact when conducted by 
well-funded research groups. The main challenge for 
the next few years will be implementation of bed-net 
programs within public health systems, and the main- 
tenance of such programs on a very small budget. 
(2) Intermittent presumptive treatment for certain 
targeted subgroups (pregnant women, especially primi- 
gravidae and perhaps also infants). 
(3) Case management of uncomplicated malaria 
remains the main means of controlling mortality and 
morbidity at present. Drug resistance in Africa is a 
threat of huge proportions, because the remaining 
effective drugs are often too expensive for routine use. 
Artemisinin combination therapy (ACT) offers theo- 
retical advantages over monotherapy treatments, but 
faces major deployment and financial hurdles. 
(4) Management of severe malaria syndromes. The 
drugs for severe disease (quinine and the artemisinins) 
are largely unaffected by resistance so far. However, 
supportive care is nearly as important as the use of an 
appropriate antimalarial drug. 
BACKGROUND 
Four species of malarial parasite cause disease in 
humans, but it is Plasmodium falciparum with which we 
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have most problems: these include its prevalence, viru- 
lence, and drug resistance. The pathogenicity of this 
parasite is thought to result from its rapid rate of asexual 
reproduction in the host and ability to sequester in 
small blood vessels. The burden of falciparum malaria is 
mainly carried by tropical Africa, where almost every- 
one becomes infected during childhood, and most mor- 
bidity/mortality is seen in children under the age of 5 
years. Most children gradually develop ‘partial immunity’, 
and this protects them from severe disease. However, 
a small proportion (but a numerically huge group) 
develops severe malaria, and this kills about a million 
people (mostly children) annually.’ Morbidity and 
mortality are also seen in young women who, although 
‘partially immune’, are at risk from severe anemia during 
pregnancy (especially their first) and may bear low- 
birthweight babies. 
In tropical countries, people with uncomplicated 
falciparum malaria are normally treated as outpatients; 
indeed, a large proportion does not seek professional 
health care, but self-medicates using drugs bought at 
local shops. Treatment is with antipyretics (paracetamol 
or aspirin) plus inexpensive oral antiparasitic drugs. 
Patients with severe malaria need (but often do not get) 
expert supportive care plus parenteral formulations of 
effective antimalarial drugs (most usually quinine or an 
artemisinin); this is often followed by oral administra- 
tion of an antimalarial drug once the patient’s condition 
improves. 
The WHO (through its Roll Back Malaria program) 
aims to halve malaria mortality by 2010. Some of the 
complementary strategies include: prevention of disease, 
case management of uncomplicated disease, and im- 
proved management of severe disease. This brief review 




Bed-nets have been used for a long time (indeed, 
Herodotus indicates their use in the Nile delta in the 
fourth century BC!), but dipping them in insecticide 
(usually pyrethroids) has given them extra benefit. The 
promise of insecticide-treated bed-nets (ITBNs) was 
shown in The Gambia during the 19805 and in Kilifi 
(Kenya) during the 199Os, where the introduction of 
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ITBNs led to significant reductions in childhood mortality 
and life-threatening malaria among children aged l-59 
months.2 More recently, a large series of studies in 
Kisumu (Kenya) has shown that ITBNs reduce child- 
hood mortality/morbidity, have major positive impacts 
on pregnant women, and even protect people who do 
not sleep under ITBNs, but who sleep within a certain 
distance of them.3 These results are very encouraging, 
but, as the investigators were the first to point out, were 
obtained by a research group with adequate funding. 
ITBNs need to be explored under ‘real-world’ circum- 
stances, i.e. small budgets and limited manpower. A start 
has been made: at Ifakara, in Tanzania, public health 
scientists are exploring the impact of ‘social marketing’ 
strategies and are studying the importance of local 
knowledge, attitudes and practices on the implemen- 
tation of such strategies.4 
Targeted chemoprophylaxis and intermittent 
presumptive treatment 
Travelers to malarial areas are encouraged to use 
effective chemoprophylaxis: they are exposed to risk 
from the drug for a limited period of time, and, crucially, 
can easily afford the intervention. In contrast, people 
who live in areas of intense transmission, were they to 
take long-term chemoprophylaxis, would be exposed to 
a cumulative risk of adverse drug reaction. Perhaps 
more importantly, very few people (or health services) 
could afford such a general measure. However, it is 
possible to target groups at high risk, namely pregnant 
women (especially those in their first or second 
pregnancy) and perhaps also young children. 
In areas of endemic transmission, malaria in preg- 
nancy is associated with severe maternal anemia and 
low-birthweight babies.5 Chloroquine (CQ) prophylaxis 
has been used in the past, and still has utility in some 
parts of Africa, but resistance to this drug is now wide- 
spread and people are turning to sulfadoxine- 
pyrimethamine (SP). Intermittent presumptive treat- 
ment (IPT) with SP once in the second trimester and 
again in the third trimester6 has high protective efficacy 
against parasitemia and anemia in HIV-negative women. 
HIV-positive women may require a monthly SP regimen, 
but even this proves to be cost-effective: the two-dose 
and monthly SP strategies cost US $11 and $14, respec- 
tively, well within the range considered to be cost- 
effective. 
Clinical malaria and severe anemia are major causes 
of hospital admission and death among infants in many 
malaria-endemic settings. Recently, IPT with SP has 
been examined in this setting, to determine its impact 
on malaria morbidity. Good protective efficacy has 
been observed against both clinical malaria and severe 
anemia.’ This is a new approach to malaria control, and 
has great potential: the WHO is planning studies to 
examine its cost-effectiveness in areas with different 
patterns of malaria endemicity. 
Critical to this ITP use of SP are (1) effectiveness, 
(2) the large therapeutic range of both component 
drugs, (3) a good safety profile, and (4) its very low 
cost. One might add slow elimination as a fourth 
critical feature of SP, but this is less clear: whether SP 
IPT works by providing chemoprophylaxis or by inter- 
mittent reduction of parasitosis is unknown. Allergy to 
sulfonamides (especially among HIV-positive people) 
is a major theoretical risk, but this does not seem to be 
a real barrier to its widespread deployment. Further- 
more, although it is an antifolate drug, SP does not 
seem to be associated with an increased risk of birth 
defects (although it must be noted that the evidence 
for SP safety in pregancy is not extensive or robust 
enough to permit strong statements). The big problem 
here is drug resistance, especially in East Africa (see 
below). 
CASE MANAGEMENT OF UNCOMPLICATED 
DISEASE 
Symptomatic patients self-select and present themselves 
for treatment, making this the simplest means of malaria 
control. First-line treatment is often obtained from local 
retail outlets, because people have little time or money, 
and the local shop is both quick and inexpensive. While 
this may prove satisfactory in a proportion of patients, 
problems are encountered: 
l People are often seeking symptomatic treatment 
for themselves or their children, and may have little 
conception of the fundamental differences between 
antipyretic drugs such as paracetamol, and antiparasitic 
medicines. Given that paracetamol and aspirin may be 
cheaper than CQ or SP, some vulnerable patients 
(especially young children) may not receive prompt 
antiparasitic drugs. 
l Drugs (both antipyretics and antimalarials) are often 
sold under proprietary names, so there is a risk of 
exceeding the recommended maximum dose of drugs 
with small therapeutic indices (like CQ; there are con- 
cerns that this trend may accelerate as CQ resistance 
worsens). 
l The dispenser is usually untrained and cannot give 
reliable advice.s Given that patients are usually poor, 
antimalarial drug doses may be unacceptably low. 
Attention is starting to be focused on the role of local 
shopkeepers, and the benefits that can be obtained 
from a limited degree of training. 
Probably about 50% of people invest their scarce funds 
to obtain antimalarial treatment and advice from the 
formal health sector. Most African countries now have 
national malaria control programs (NMCPs) which pub- 
lish guidelines on antimalarial drug policy. It is worth 
taking a little time now to examine the drugs available 
and consider the plight that NMCP managers find them- 
selves in. 
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Chloroquine and amodiaquine 
CQ remains the first-line treatment for uncomplicated 
falciparum malaria in much of Africa, even in areas 
of high-level resistance. CQ is cheap, safe and well 
tolerated, but its failure to eliminate parasitemia may 
eventually lead to the development of profound anemia. 
Uganda, faced with high CQ failure rates, has recently 
decided to use a combination of CQ and SP for uncom- 
plicated malaria. This combination has been little studied, 
and there is no evidence of advantages over SP alone. 
However, there is logic underpinning the combination: 
Despite a high prevalence of CQ resistance, the drug 
retains some clinical efficacy in a high proportion of 
patients, lowering parasitemia and fever more rapidly 
than SP This may reduce the risk of severe malaria 
compared with the use of SP alone. 
The likelihood of encountering a parasite isolate 
resistant to both SP and CQ is lower than that for 
either drug alone. 
The cost of CQ plus SP, although higher than for 
either drug alone, is still readily affordable in an 
African setting. 
The adverse event profiles of CQ and SP differ widely. 
One would therefore expect that the proportion of 
patients suffering an adverse event from SP plus CQ 
would be roughly additive. However, it would not 
necessarily be the case that the risk of serious adverse 
events would behave in the same additive manner, 
and the risk of synergistic toxicity between CQ and SP 
is small. 
Clearly, studies are now needed to investigate the benefits 
of the CQ-SP combination. The Ugandan authorities, 
faced with a dire public health threat, have decided to 
act now, and obtain data later. 
Amodiaquine (AQ), a close congener of CQ, may 
still be useful in some circumstances where established 
CQ resistance precludes the use of CQ for uncompli- 
cated malaria. Furthermore, there is evidence of the 
utility of AQ in combination with other drugs.9 
Sulfadoxine-pyrimethamine 
In many parts of Africa, a decision must soon be made 
to replace CQ as the first-line treatment for falciparum 
malaria. The switch to SP has already been made in 
many countries (Malawi, the forerunner, having done so 
in 1993): this drug has the great advantages of being 
(1) able to be given as a single-dose treatment, and (2) 
inexpensive. The prediction has been that resistance will 
develop to SP within a few years, facilitated by the slow 
elimination of SP from the body. Malawi does have 
evidence of worsening SP resistance,lO but the process 
has not been as rapid as one might have feared, and 
many lives have certainly been saved by the timely 
change in national policy in 1993. However, although the 
drug still works, there is little doubt that the situation is 
worsening: for example, the SP failure rate in Muheza 
(Tanzania) has now reached alarming levels.il Thus, one 
of the most important questions is: what drug (or drugs) 
comes next? Worryingly for public health in Africa, there 
is no easy answer. 
Chlorproguanil-dapsone (CPG-DDS; LAPDAP) 
This is not yet commercially available, but is being 
developed (by GlaxoSmithKline in partnership with 
The UNDP/World Bank/WHO Special Program for 
Research and Training in Tropical Medicine, the 
Department for International Development and the 
University of Liverpool) primarily for the treatment of 
semi-immune patients in tropical Africa, where there is an 
urgent need for an inexpensive alternative to pyrime- 
thamine combinations. Daily CPG-DDS for 3 days (CPG 
2.0 mg/kg and DDS 2.5 mg/kg daily) is an effective 
treatment for uncomplicated falciparum malaria in semi- 
immune patients,12 and seems to be well tolerated. 
CPG-DDS costs less than US$ 0.50 for a 3-day adult 
treatment course in the public sector. There is evidence 
that SP treatment of parasite strains with dhfr mutations 
at positions 108,51 and 59 often results in clinical failure; 
in contrast, the risk of clinical failure seems lower with 
CPG-DDS.lOJ* It is also probable that CPG-DDS exerts 
a smaller degree of selection pressure for resistance than 
SP.i3 All of this sounds good, but what are the caveats? 
. Effectiveness. CPG-DDS is highly efficacious in the 
clinical trial setting, but this drug combination is 
eliminated very rapidly from the body,14,15 and poor 
compliance might have a major impact on outcome. 
There is thus a need to examine the ‘real-world’ 
effectiveness of the drug. 
Safety. The safety of CPG-DDS will be judged by 
national regulatory authorities (including the UK 
Medicines Control Agency). However it is charac- 
teristic of such dossiers that they contain data on 
about 2000-3000 people, whereas life-threatening 
adverse drug reactions often have a prevalence of 
about 1: 5000 or 1: 10 000. Thus it will not be possible 
to assume that we fully understand the safety profile 
of CPG-DDS until post-marketing surveillance data 
are available. 
Selection of drug resistance. The available evidence 
suggests that CPG-DDS selects resistance less 
readily than SP. However, we need to see whether 
resistance is selected when the drug is in widespread 
use in the ‘real world’ (when the ideal regimen may 
not be followed). 
In short, assuming that CPG-DDS is given regulatory 
approval, there is probably a need for a phase IV pro- 
gram to examine these issues, before the large-scale 
adoption of CPG-DDS into NMCPs is considered. 
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Quinine 
This is an effective replacement for CQ and is a drug of 
choice for non-immune patients with falciparum 
malaria. However, it has the disadvantage that it must 
be taken three times a day for 7 days, tastes bitter, 
and predictably causes unpleasant symptoms at normal 
therapeutic doses: thus compliance is a major problem. 
In those parts of South East Asia where parasite sensi- 
tivity to quinine is declining, and where few alternatives 
are available, cure rates are improved if the drug is 
combined with tetracycline or clindamycin. 
Mefloquine 
This is given as a single dose (or in divided doses 6-8 h 
apart to reduce the risk of vomiting), and was initially 
highly effective against multiresistant strains of falci- 
parum malaria throughout the world. However, in some 
areas, notably in the border regions of Thailand, 
mefloquine resistance has developed rapidly, and a com- 
bination of melfoquine with artesunate is currently used. 
The relatively high cost of mefloquine limits its useful- 
ness in Africa. 
Atovaquone-proguanil 
This is an effective and well-tolerated drug, but its price 
puts it well out of reach for the majority of people in 
Africa. 
Artemisinin ‘combination therapy’ (ACT) 
During treatment with two (or more) drugs, the chance 
of a mutant resistant to both drugs emerging can be 
calculated from the product of the individual per- 
parasite mutation rates (assuming that the resistance 
mutations are not ‘linked’). The artemisinin derivatives 
reduce the parasite biomass by around 4 logs for each 
asexual cycle: this makes them the most rapidly effi- 
cacious antimalarial drugs in use.16 This rapid reduction 
of the parasite biomass has a major theoretical role 
when artemisinin derivatives are combined with another 
antimalarial drug: the parasite population available to 
develop mutations to the second drug is reduced by 
several log orders. Thus, when mefloquine was used in 
combination with artemisinin drugs in Thailand, the rate 
of development of mefloquine resistance was reduced.i’ 
It now seems likely that the WHO will recommend ACT 
as part of the ‘ideal’ strategy for malaria control in Africa, 
but there are practical concerns. 
1. ACT will be relatively expensive. There is only one 
fixed-ratio combination, lumefantrine with artemether 
(Coartem; Riamet), and this will be made available 
for around US$ 2.50 per adult treatment course. 
This is generous and courageous of the manufacturer 
(in Switzerland, Riamet is selling at SFr. 78.50 (US$ 
2. 
3. 
57.00) for a 3-day adult course’*) and a singular 
success for the WHO ‘Roll Back Malaria’ negotiators. 
However, there are still problems: (a) US$2.50 is still 
too much for the generalized use of Coartem as first- 
line treatment by most African nations; and (b) there 
is concern that the concessionary price may prove to 
be unstable-it represents an awesome commitment 
by the manufacturer-unless the new Global Fund 
can contribute large revenue costs. Work has started 
on the development of a chlorproguanil-dapsone- 
artesunate (CDA) triple-combination tablet. This 
is being done by a public-private partnership that 
involves the Medicine for Malaria Venture (MMV). 
The real cost of CDA will probably be much less than 
that of lumefantrine-artemether, but its development 
is likely to take another 2-3 years. 
ACT has been shown to work in Thailand, but it is not 
clear that the same will apply in a real-world African 
setting, and the hospital-based clinical trials in 
progress at the moment will probably offer only 
supportive evidence. The large-scale population- 
based trials planned for Tanzania and Mozambique 
should provide definitive answers, but will take several 
years to complete. 
Finally, a great deal of operational work will be 
needed to ensure smooth translation of ACT from 
policy into implementation. The complicated dosage 
regimen of Coartem (twice daily for 3 days) poses a 
challenge in this regard. 
Of course, any new initiative is surrounded by doubt and 
beset by practical difficulty: the above concerns are not 
reasons to set ACT aside. They do, however, need to be 
addressed. 
WHAT HAPPENS WHEN A FIRST-LINE 
DRUG FAILS? 
Life-threatening malaria can evolve within a day of 
the first symptom, so that even if an effective drug is 
available for uncomplicated disease, the patient may still 
develop life-threatening illness before treatment can be 
given. One would predict that the use of an ineffective 
first-line drug would carry an increased risk of deterio- 
ration to severe malaria, and this seems to be the case.‘” 
The population at most risk from severe malaria world- 
wide is the under-5 age-group in Sub-Saharan Africa, 
and the two main syndromes are cerebral malaria and 
severe anemia. Falciparum malaria can cause many other 
life-threatening syndromes, but these are beyond the 
scope of the present article (see the excellent WHO 
summary of severe and complicated malaria20). 
Cerebral malaria 
Unlike the other species of malarial parasite, Plasmodium 
fulciparum can cause acute life-threatening encephalo- 
pathy loosely referred to as ‘cerebral malaria’. The 
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diagnostic feature is unrousable coma, seizures being 
very common (especially in children). Momentary 
reflection will reveal that unrousable coma can be multi- 
factorial, possible causes including hypoglycemia, recent 
(or ongoing) seizure, severe acidosis, and the prior use 
of sedative antiepileptic drugs at high doses. Thus, 
although sequestration of parasites in the cerebral micro- 
circulation is considered to be the prime cause of 
‘cerebral malaria’, the clinical case definition is not 
homogeneous, and is thus associated with a wide variety 
of prognoses. For an unconscious patient in whom 
falciparum malaria is suspected, the basic principles of 
management can be summarized as follows: 
l Treatment should be started immediately the diag- 
nosis is suspected. 
l A drug regimen should be chosen appropriate for the 
known local pattern of drug resistance: quinine and 
the artemisinin derivatives are the preferred drugs for 
severe malaria. 
l Dosage should be calculated according to the patient’s 
body weight, rather than estimated. 
l The antimalarial drug should be given parenterally 
where possible. 
l If quinine is being used, then a loading dose should 
be given unless the patient has received parenteral 
quinine/ quinidine or oral halofantrine within the pre- 
vious 24 h. 
l Therapeutic response should be monitored frequently 
by: 
clinical assessment; 
examination of blood films; measurement of blood 
glucose, temperature, pulse, and blood pressure. 
Antimalarial drugs should be given orally as soon 
as patients are able to swallow and retain tablets. 
Use of quinine in severe malaria syndromes 
Quinine has a narrow therapeutic range, and doses 
should always be adjusted for body weight. A loading 
dose should be given to achieve therapeutic concen- 
trations more rapidly: the practice is based largely upon 
sound pharmacokinetic data and empirical medical 
practice. If patients develop severe malaria following 
mefloquine treatment, a full dose of quinine should be 
given: there is no evidence that mefloquine and quinine 
in combination are cardiotoxic.21 Quinine must never be 
given as a bolus intravenous injection: the risk of serious 
adverse reactions, including shock and arrhythmias, is 
high. The preferred means of administration is by slow, 
constant-rate infusion of the drug diluted in crystalloid 
solution. If neither infusion pump nor burette is avail- 
able, then the drug may be added to intravenous fluid 
in the bag.** This may be difficult in young children 
because of the need for caution with fluid volumes. If 
intravenous administration is impossible, quinine may 
be given intramuscularly. .23,24 the doses are identical to 
those used intravenously. Coagulopathy is a relative 
contraindication to this route, but quinine is absorbed 
reliably even in the sickest patients. The dose should 
be diluted (up to 1 : 5 v/v) with water for injections, as 
undiluted quinine dihydrochloride 300 mg/mL has a pH 
of 2 and is very painful. The loading dose should be 
divided between two or more sites.z5 
Maintenance quinine doses are usually given every 
8 h, but in African children 12-hourly maintenance is 
effective.24 In South East Asia, quinine (combined with 
either tetracycline or clindamycin) is given for 7 days: 
shorter courses are associated with recrudescences. 
Courses are generally shorter in semi-immune African 
patients (5 days being standard in many countries), and 
combination with antibiotics or SP is not usual. 
Frequent blood glucose measurements are man- 
datory for patients on parenteral quinine, because of the 
risk of drug-induced hypoglycemia: the preferred 
frequency of measurement varies between cases, and 
clinical judgement should be used. If possible, blood 
slides should be examined 6-hourly, and a quantitative 
parasite count done. Parasite counts often remain un- 
changed, and may rise, during the first 18-24 h of treat- 
ment with quinine: this is not reliable evidence for drug 
failure. After 24 h of treatment, counts usually fall in 
a log-normal manner, and asexual parasitemia should 
disappear within 5 days (gametocytes may persist, but 
they are non-pathogenic and of no clinical, although of 
some public health, relevance). A rising, or unchanging, 
parasite count after 24 h of quinine treatment may 
indicate drug resistance: this is particularly likely in 
infections acquired in South East Asia. 
Use of the artemisinins in severe malaria syndromes 
Because of the rapid reduction in total body parasite 
load with the artemisinin drugs, one might predict better 
clinical outcome than with quinine. Disappointingly, a 
large meta-analysis 26 showed no statistically significant 
differences between artemether and quinine in case 
fatality, coma recovery, fever clearance times, or the 
development of neurologic sequelae. However, combined 
‘adverse outcome’ (death or sequelae) was significantly 
less common in the artemether group, and subgroup 
analyses suggested that, in adults and in Asian patients, 
artemether was significantly more effective than quinine 
in reducing mortality: this might have been due to the 
greater prevalence of quinine resistance in Asia. 
Artemether is usually dispensed in l-ml ampoules 
containing 80 mg artemether in peanut oil. An initial 
loading dose is recommended, followed by once-daily 
administration of the maintenance dose for at least 3 
days or until an oral formulation of an artemisinin or 
another antimalarial drug can be taken by mouth. 
Currently, only artesunate is available for intra- 
venous administration.27,28 A loading dose of artesunate 
is given by intravenous bolus injection, followed by a 
maintenance dose given at 12 and 24 h and then daily to 
complete 7 days of treatment. 
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Suppositories of artemisinin and artesunate29 have 
proved effective in adults and children with cerebral and 
other forms of severe malaria in China and South East 
Asian countries. Although plasma concentration profiles 
are more erratic than with intravenous administration, 
inadequate absorption is unusual. This is a particularly 
promising route of administration for use at the most 
peripheral level of the health service, and trials are being 
conducted by the WHO. 
Supportive care in severe malaria syndromes 
Important though the choice and correct use of anti- 
parasitic drugs are, patients also need expert supportive 
care.20 This includes the management of hypoglycemia 
and acidosis, seizures, brain swelling, coagulopathy, renal 
failure, and pulmonary edema. Detailed consideration 
of such intensive care management is outside the scope 
of the present article. 
Management of severe anemia 
Where blood, competently screened for important 
pathogens (such as HIV and the hepatitis viruses), is 
available, transfusion with packed cells (90% of plasma 
removed) or whole blood should be considered when 
the hematocrit falls towards 20%.‘” Where screening 
of transfused blood is inadequate, and infections such 
as HIV are prevalent, criteria for blood transfusion have 
become much more strict. Under these conditions, plasma 
expanders (colloids) and oxygen should be used, and 
clinical features such as shock, cardiac failure, hypoxia 
and extreme lethargy, rather than an arbitrary hemato- 
crit value, should be used as an indication for trans- 
fusion. However, a hematocrit of 15% in a normally 
hydrated child or adult is probably an absolute indication 
for blood transfusion. High parasitemia (a presage of 
massive hemolysis), active or predicted bleeding (e.g. in 
a woman about to give birth) and other severe com- 
plications are other powerful indications for transfusion.26 
CONCLUSIONS 
I! falciparum remains an immense public health problem 
in Africa, where drug resistance now threatens to cause 
a major increase in mortality and morbidity. The main 
ways in which we may be able to control this problem 
are: (1) ITBNs, (2) IPT for pregnant women (and perhaps 
also for infants); (3) improved case management of 
uncomplicated disease; and (4) improved management 
of severe malaria syndromes. All of these strategies are 
faced by major challenges: 
l ITBNs work in the research setting: we now have to 
make them effective and sustainable in the real world 
(on a very limited budget). 
l Drugs for uncomplicated malaria and for IPT need to 
be effective (in a real-world setting, rather than simply 
in clinical trials), safe, inexpensive, and not prone 
to selection of resistance. This is a tall order. ACT is 
likely to be the preferred option of the WHO, but 
faces hurdles, including the practicalities of imple- 
mentation, sustainable finance, and safety. The role of 
new monotherapy drugs (including CPG-DDS) is yet 
to be defined. 
l Antimalarial drugs for severe malaria syndromes 
(mainly quinine and the artemisinins) are not currently 
threatened by drug resistance in Africa. The key to 
reducing mortality and morbidity in this setting is 
optimization of practical supportive care measures 
(including the use of blood transfusion). 
To hold our ground against malaria, there will need to be 
continued collaboration between scientists, the pharma- 
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